IMDX
NASDAQInsight Molecular Diagnostics Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Price$5.35+0.11 (+2.20%)
01:30 PM07:45 PM
News · 26 weeks40+60%
2025-12-282026-06-21
Mix2690d
- SEC Filings9(35%)
- Insider8(31%)
- Other5(19%)
- Offering2(8%)
- Earnings2(8%)
Latest news
25 items- PRiMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation- NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), and the American Society of Transplant Surgeons (ASTS) today announced the selection of Kenneth Andreoni, MD, Surgical Director of Kidney Transplantation at Thomas Jefferson University, and Kenneth Chavin, MD, MBA, PhD, FACS, of Temple Health, as the recipients of the ASTS-iMDx Research Grant for Understanding the Health Economics of In-House versus Send-Out of donor-derived cell-free DNA (dd-cfDNA) testing. The pursuit of this research is timely as the transpla
- SECInsight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- PRFavorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical ChemistryPeer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitorGraftAssure's industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the premier, peer-reviewed scientific publication of the Association for Diagnostics & Laboratory Medicine. The article highlights the concordant performance between iMDx's digital-PCR-based flagship
- INSIDERDirector Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERDirector Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERDirector Arno Andrew was granted 32,331 shares, increasing direct ownership by 24% to 168,885 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- PRIMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of TransplantationAmerican Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA aloneGraftAssure™ assay doubles reliability of positive results in screening cohortIn for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80% NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced an online published article in the American Journal of Transplantation asserting statistical superiority of the company's flagship GraftAssure transplant rejection monitoring assay. IMDx's newly develope
- PRiMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant CongressMultiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specificallyMajor transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applicationsiMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced it will be highlighting its GraftAssure™ technology at the upcoming American Transplant Congress, to be held in Boston fro
- SECSEC Form 10-Q filed by Insight Molecular Diagnostics Inc.10-Q - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECInsight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECAmendment: Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K/A - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- PRIMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure CommercializationProgressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagementNortheast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC studyBooked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming daysAnticipate significant U.S. orders to follow FDA marketing authorizationEncouraging dialogue with FDA supports expected authorization later in 2026 NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (NASDAQ:IMDX), today published the following letter to shareholders in conjunction with its
- PRiMDx to Release First Quarter 2026 Results on May 13, 2026NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on Wednesday, May 13, 2026, then host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q1 2026 Earnings Webinar. An archived replay will be available after the call concludes on iMDX's website within the Investors/Events & Presentations section here. About Insight Molecular Diagnostics Inc.Insight Molec
- SECSEC Form DEFA14A filed by Insight Molecular Diagnostics Inc.DEFA14A - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECSEC Form DEF 14A filed by Insight Molecular Diagnostics Inc.DEF 14A - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECInsight Molecular Diagnostics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Insight Molecular Diagnostics Inc.SCHEDULE 13D/A - Insight Molecular Diagnostics Inc. (0001642380) (Subject)
- INSIDERLarge owner Broadwood Partners, L.P. bought $2,032,251 worth of shares (570,184 units at $3.56) (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERSEC Form 4 filed by Broadwood Partners, L.P.4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- PRReal-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure AssayPositive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, ScotlandThree posters to be presented at the 63rd European Renal Association (ERA) Congress, June 3–6, 2026 in Glasgow, ScotlandFavorable real-world evidence poster to be presented at the American Transplant Congress (ATC), June 20–24, 2026 in BostonUnaudited first quarter 2026 cash balance of $29.4 million is in line with year-end and Q4 2025 conference call guidanceCompany to host fireside chat and one-on-one meetings with investors at Needham Virtual Healthcare Conference on Wednesday, April 15th NAS
- INSIDERSEC Form 4 filed by James Andrea S.4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERSEC Form 4 filed by Liu James Yang4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERSEC Form 4 filed by Riggs Josh4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- SECSEC Form 10-K filed by Insight Molecular Diagnostics Inc.10-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECInsight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
IMDX FAQ
4 questionsWhere does IMDX stock trade?
Insight Molecular Diagnostics Inc. (IMDX) is listed on NASDAQ.What sector and industry is IMDX in?
Insight Molecular Diagnostics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What companies are similar to IMDX?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare IMDX side-by-side with any of them on Quantisnow.How can I track IMDX on Quantisnow?
Quantisnow aggregates Insight Molecular Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMDX to receive live email and push alerts on every new disclosure.